RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been assigned a consensus recommendation of “Hold” from the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $9.50.

Several analysts have recently commented on RAPT shares. UBS Group lowered their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research report on Monday, September 9th. HC Wainwright reiterated a “neutral” rating on shares of RAPT Therapeutics in a report on Monday, November 25th. Stifel Nicolaus reissued a “hold” rating and issued a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Finally, Wells Fargo & Company dropped their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th.

Institutional Trading of RAPT Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Readystate Asset Management LP acquired a new stake in shares of RAPT Therapeutics in the third quarter worth approximately $36,000. Barclays PLC grew its stake in shares of RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares during the period. XTX Topco Ltd acquired a new stake in shares of RAPT Therapeutics during the 2nd quarter worth $108,000. Hennion & Walsh Asset Management Inc. raised its position in shares of RAPT Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after buying an additional 3,824 shares during the period. Finally, Exchange Traded Concepts LLC boosted its holdings in RAPT Therapeutics by 244.7% in the third quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock valued at $179,000 after acquiring an additional 63,235 shares during the last quarter. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Stock Performance

Shares of RAPT stock opened at $1.17 on Tuesday. The stock has a fifty day moving average price of $1.70 and a 200 day moving average price of $2.45. The stock has a market cap of $40.90 million, a PE ratio of -0.42 and a beta of 0.07. RAPT Therapeutics has a 1 year low of $0.92 and a 1 year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, equities research analysts predict that RAPT Therapeutics will post -2.77 earnings per share for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.